pashamylaram

Suven Life Sciences (Suven) has secured one product patent from Brazil and one product patent from Eurasia corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2023 and 2034 respectively. The granted claims of the patents include the class of selective 5-HT6 and 5-HT4 … Read more